Most importantly, alpelisib-therapy in NSGS mice bearing nilotinib-resistant K562 cells significantly reduces leukemia burden and increases the survival time of leukemic mice, mechanistically through suppression of PI3K signaling mediators like F2R, CyclinD1 and PDGFR. Here, F2R is linked to leukemia.